Anna Kurzyna Solinas, MD
Medical Oncology · Lake Success, NYNPI 1922009653
Payments from drug & device makers
Across 76 payments — averaging $49.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- AstraZeneca$461
- Daiichi Sankyo Inc.$252
- Incyte Corporation$250
- Novartis$243
- Johnson & Johnson$147
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,64197%
- Education$1193%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 12 | $1,043 |
| AstraZeneca(2 entities) | 11 | $461 |
| Daiichi Sankyo Inc. | 2 | $252 |
| Incyte Corporation | 2 | $250 |
| Novartis | 16 | $243 |
| Johnson & Johnson | 1 | $147 |
| Adaptive Biotechnologies Corporation | 1 | $132 |
| Mirati Therapeutics, Inc. | 1 | $125 |
| Verastem, Inc. | 1 | $125 |
| Pharmaessentia USA Corporation | 1 | $121 |
| Puma Biotechnology, Inc. | 1 | $120 |
| Merck | 1 | $116 |
| Geron Corporation | 3 | $104 |
| Amgen | 1 | $103 |
| Bristol Myers Squibb | 4 | $88 |
| Pfizer | 4 | $73 |
| Seagen Inc. | 3 | $55 |
| Genentech USA, Inc. | 2 | $41 |
| EMD Serono, Inc. | 2 | $40 |
| GSK | 2 | $37 |
| Lilly USA, LLC | 2 | $32 |
| Springworks Therapeutics, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $17 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,760 in reported general payments places this provider in the 30th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 19 | $66,831 |
| Anastrozole | 41 | $554 |
| Hydroxyurea | 15 | $327 |
| Prednisone | 19 | $142 |
| Ciprofloxacin Hcl | 14 | $134 |
| Atorvastatin Calcium | 24 | $120 |
| Gabapentin | 12 | $101 |
| Zolpidem Tartrate | 18 | $68 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $35 |
| Amlodipine Besylate | 16 | $30 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Lake Success
- Anthony MatoIthaca$40.3M
- Robert MotzerNew York$32.8M
- Alan HoNew York$32M
- Michael MorrisNew York$30.4M
- Matthew GalskyNew York$28.1M
- Wungki ParkNew York$25.5M
- Komal JhaveriNew York$22.3M
- Joshua RichterNew York$19.9M
- Jia RuanNew York$19.8M
- Andrea CercekNew York$17.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.